Dificid (fidaxomicin) / Merck (MSD), Astellas 
Welcome,         Profile    Billing    Logout  
 11 Diseases   2 Trials   2 Trials   1263 News 


«12345678910111213...1617»
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    A Rare Case of Erosive Gastritis and Melena Related to Gastric Mucosal Calcinosis (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_3283;    
    He had been hospitalized one week prior for peritonitis, which was treated with vancomycin and ceftazidime...He was started on fidaxomicin for C. diff colitis...Figure: Figure 1. Endoscopic appearance of gastric mucosal calcinosis
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas, Zinplava (bezlotoxumab) / Merck (MSD)
    Look What the Cat Dragged In! Community-Acquired Clostridiodes difficile Infection From a Household Cat (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_2155;    
    1 month later, a trial taper of vancomycin and fidaxomicin was given for recurrent C. difficile...5 months after the initial infection, she was referred for colonoscopy and treated with bezlotoxumab with minimal improvement; now with a plan to pursue FMT...This graphic depicts the epidemiological triangle of infectious disease. Focusing on the interaction between the host, the environment and the pathogen can help us understand this rare case of community acquired C. difficile.
  • ||||||||||  A Rare Case of Refractory Immune Checkpoint Inhibitor Colitis Complicated by Concurrent Clostridioides difficile Infection (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_688;    
    A PCR was positive for CDI and the patient was prescribed PO Vancomycin...She was started on fidaxomicin and high-dose steroids...Fecal microbiota transplantation (FMT) has been described as a successful treatment option for ICI colitis with superimposed CDI resistant to antibiotics, steroids, IFX, and vedolizumab...Figure c: Flexible sigmoidoscopy image 1. Figure d: Flexible sigmoidoscopy image 2
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    A Novel Treatment Approach to Treatment-Resistant, Recurrent C. diff (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_610;    
    Fecal transplant then restores the normal gut microbiome composition, rendering C. Diff growth incapable of producing clinically significant disease. The aim of this case report is to equip clinicians with meaningful evidence to improve cure rates in treatment-resistant, recurrent C. Diff patients with an exemplary protocol ensuring success due to low bacterial and spore levels prior to fecal transplant.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
    A Case of Invasive Gastrointestinal Mold Infection (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_535;    
    Initial hospitalization was complicated by neutropenic fever and C. difficile enteritis treated with Fidaxomicin...He was treated with Valganciclovir and initiated on TPN...He was treated with liposomal Amphotericin B then transitioned to oral Isavuconazole before making a full recovery...Figure: (A, B) Circumferential ulcerations seen in the small bowel on push enteroscopy. (C) Mucosal ulceration with underlying necrotizing granulomatous inflammation in the deep muscularis propria/pericolonic adipose tissue with non-septated fungal hyphae present.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Review, Journal:  Micrococcin P2 Targets Clostridioides difficile. (Pubmed Central) -  Aug 31, 2022   
    Thus, micrococcin P2 is a valuable platform to be exploited for the development of new anti-C. difficile antibiotics.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Review, Journal:  Clostridioides Infection in Patients with Inflammatory Bowel Disease (Pubmed Central) -  Aug 26, 2022   
    As CDI may worsen the clinical outcomes of IBD, patients should be carefully monitored and an escalation of IBD therapy needs to be considered when there is no improvement seen with the antimicrobial treatment of CDI. This review discusses the risk, pathophysiology, diagnosis, and management of CDI in IBD.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Review, Journal:  How to: Clostridioides difficile infection in children. (Pubmed Central) -  Jul 28, 2022   
    If CDI laboratory testing is indicated in children with diarrhoea, the likelihood of C. difficile colonisation and coinfection with other intestinal pathogens should be considered. The currently available data support a change in the treatment strategy of CDI in children.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Journal:  A roadmap for designing narrow-spectrum antibiotics targeting bacterial pathogens. (Pubmed Central) -  Jul 23, 2022   
    In contrast, Fidaxomicin (Fdx) is a narrow-spectrum antibiotic that inhibits Cdiff growth without affecting crucial gut microbes...This finding was further corroborated by biochemical, bioinformatics, and genetic analysis. This microreview describes implications of this work for lineage-specific antibiotic design and new directions toward understanding transcription and regulation in Cdiff and other bacterial pathogens.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Retrospective data, Journal:  Treatment and Outcomes of Clostridioides difficile Infection in Switzerland: A Two-Center Retrospective Cohort Study. (Pubmed Central) -  Jul 11, 2022   
    The Charlson Comorbidity Index score (p < 0.001), leukocytes > 15 G/L (p = 0.008), and the use of metronidazole (p = 0.012) or vancomycin (p = 0.049) were factors associated with the composite outcome. Our study provides valuable insights on CDI treatment and outcomes in Switzerland, highlights the heterogeneity in practices among centers, and underlines the need for the active monitoring of clinical practices and their impact on clinical outcomes through large multicentric cohorts.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Reimbursement, Journal, Medicare:  Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection. (Pubmed Central) -  Jul 10, 2022   
    Oral vancomycin and fidaxomicin, frontline Clostridioides difficile treatments, were on formulary for 100% (42,314,676/42,314,676) and 84.1% (35,598,385/42,314,676) of enrollees, respectively. However, they were broadly accessible (formulary, unrestricted, Tier 1 or 2) to only 14.4% (6,104,348/42,314,676) and 1.1% (483,004/42,314,676), respectively.
  • ||||||||||  Mycobutin (rifabutin) / Pfizer, Lupin, Dificid (fidaxomicin) / Merck (MSD), Astellas
    Journal:  Going Retro, Going Viral: Experiences and Lessons in Drug Discovery from COVID-19. (Pubmed Central) -  Jul 1, 2022   
    We discuss the implications of these and other findings for computational studies predicting the binding of ligands to large and flexible protein complexes and therefore for drug discovery or repurposing efforts utilizing such studies. Finally, we suggest several improvements on such efforts ongoing against SARS-CoV-2 and future pathogens as they arise.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Preclinical, Journal:  In vitro activity of fidaxomicin against nontuberculosis mycobacteria. (Pubmed Central) -  Jun 22, 2022   
    Macrolide antibiotics, such as clarithromycin and azithromycin, are the key drugs for treating NTM infections...Fidaxomicin, rifampicin and clarithromycin were tested against M. abcessus complex subspecies 14 M. abscessus and 5 M. massiliense strains for inducible resistance determination.Results...Fidaxomicin has high in vitro activity against most of the NTM reference strains and some prevalent NTM clinical isolates. This promising finding warrants further investigation on the actions of fidaxomicn in vivo and as a potential antibiotic for NTM treatment.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas, Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma, RT002 / Retrotope
    Journal:  Clostridioides (Clostridium) difficile isolated from paediatric patients in Western Australia 2019-2020. (Pubmed Central) -  Jun 8, 2022   
    This study provides a baseline for future surveillance of paediatric CDI in Australia. Given that young children can be asymptomatically colonised with toxigenic C. difficile strains, they represent a potential reservoir of strains causing CDI in adults.